Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04677413 · ClinicalTrials.gov registry record · Phase 1
Ultra-fractionated Radiotherapy for Rectal Cancer
A Phase 1 study of Rectal Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT04677413: Recruiting Phase 1 study of Rectal Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT04677413 is a Phase 1 study of Rectal Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 27 participants, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04677413, a Phase 1 study of Rectal Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a prolonged interval, at escalated doses and with concurrent chemotherapy may be feasible and allow for improved clinical response.
Primary Outcome
The MTD will be based upon toxicity, which will be assessed according to the NCI's CTCAE v5.0 toxicity criteria. Dose limiting toxicities will include any of the following Grade 3+ GI toxicities.
Conditions Studied
Interventions
- RADIATION Ultrafractionated radiotherapy for rectal cancer
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-06-03 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT04677413 shows while recruiting
NCT04677413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ultrafractionated radiotherapy for rectal cancer is the first listed.
NCT04677413 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04677413 about?
NCT04677413 is a clinical study titled "Ultra-fractionated Radiotherapy for Rectal Cancer". The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a p...
What is the current status of trial NCT04677413?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2021-06-03. Estimated completion is 2026-06.
What conditions does trial NCT04677413 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT04677413?
The interventions under investigation include: Ultrafractionated radiotherapy for rectal cancer (RADIATION).
Who is sponsoring clinical trial NCT04677413?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04677413 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04677413's enrollment target sits among peer trials
27 56th of 70 higher than 15 of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
F-Tryptophan PET/CT in Human Cancers
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
RECRUITING · Phase 1
-
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy